Compare Torrent Pharma with Lupin Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs LUPIN - Comparison Results

TORRENT PHARMA     Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

LUPIN 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA LUPIN TORRENT PHARMA/
LUPIN
 
P/E (TTM) x 65.1 -70.8 - View Chart
P/BV x 7.7 2.1 365.4% View Chart
Dividend Yield % 0.8 0.0 -  

Financials

 TORRENT PHARMA   LUPIN
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-19
LUPIN
Mar-19
TORRENT PHARMA/
LUPIN
5-Yr Chart
Click to enlarge
High Rs1,964986 199.2%   
Low Rs1,245720 172.8%   
Sales per share (Unadj.) Rs453.4369.5 122.7%  
Earnings per share (Unadj.) Rs25.813.4 192.3%  
Cash flow per share (Unadj.) Rs62.337.4 166.6%  
Dividends per share (Unadj.) Rs17.000-  
Dividend yield (eoy) %1.10-  
Book value per share (Unadj.) Rs279.2303.7 91.9%  
Shares outstanding (eoy) m169.22452.49 37.4%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.52.3 153.2%   
Avg P/E ratio x62.263.6 97.8%  
P/CF ratio (eoy) x25.822.8 112.9%  
Price / Book Value ratio x5.72.8 204.6%  
Dividend payout %65.90-   
Avg Mkt Cap Rs m271,513386,064 70.3%   
No. of employees `00013.617.7 76.9%   
Total wages/salary Rs m14,03831,513 44.5%   
Avg. sales/employee Rs Th5,642.69,453.8 59.7%   
Avg. wages/employee Rs Th1,032.41,782.0 57.9%   
Avg. net profit/employee Rs Th320.9343.0 93.5%   
INCOME DATA
Net Sales Rs m76,728167,182 45.9%  
Other income Rs m5713,640 15.7%   
Total revenues Rs m77,299170,822 45.3%   
Gross profit Rs m19,83128,822 68.8%  
Depreciation Rs m6,17710,850 56.9%   
Interest Rs m5,0383,078 163.6%   
Profit before tax Rs m9,18718,534 49.6%   
Minority Interest Rs m0-89 0.0%   
Prior Period Items Rs m038 0.0%   
Extraordinary Inc (Exp) Rs m-3,570-3,400 105.0%   
Tax Rs m1,2549,017 13.9%   
Profit after tax Rs m4,3636,066 71.9%  
Gross profit margin %25.817.2 149.9%  
Effective tax rate %13.648.7 28.0%   
Net profit margin %5.73.6 156.7%  
BALANCE SHEET DATA
Current assets Rs m50,375138,536 36.4%   
Current liabilities Rs m51,65361,299 84.3%   
Net working cap to sales %-1.746.2 -3.6%  
Current ratio x1.02.3 43.2%  
Inventory Days Days9284 109.9%  
Debtors Days Days68112 60.7%  
Net fixed assets Rs m83,648127,516 65.6%   
Share capital Rs m846905 93.5%   
"Free" reserves Rs m46,397136,517 34.0%   
Net worth Rs m47,244137,422 34.4%   
Long term debt Rs m39,12966,417 58.9%   
Total assets Rs m141,209279,494 50.5%  
Interest coverage x2.87.0 40.2%   
Debt to equity ratio x0.80.5 171.4%  
Sales to assets ratio x0.50.6 90.8%   
Return on assets %6.73.3 203.5%  
Return on equity %9.24.4 209.2%  
Return on capital %12.38.9 138.5%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m22,10359,414 37.2%   
Fx outflow Rs m5,52222,282 24.8%   
Net fx Rs m16,58137,132 44.7%   
CASH FLOW
From Operations Rs m17,98116,660 107.9%  
From Investments Rs m-2,413-32,825 7.4%  
From Financial Activity Rs m-13,1457,441 -176.6%  
Net Cashflow Rs m2,380-8,724 -27.3%  

Share Holding

Indian Promoters % 71.5 46.6 153.4%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 7.0 11.3 62.1%  
FIIs % 12.6 31.9 39.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 10.1 87.1%  
Shareholders   26,511 98,259 27.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   STRIDES PHARMA SCIENCE  AJANTA PHARMA  UNICHEM LAB  ALEMBIC PHARMA  CADILA HEALTHCARE  

Compare TORRENT PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

How to Trade this Market Crash(Podcast)

India's #1 trader, Vijay Bhambwani, decodes the crash...and reveals hidden opportunities one could profit from.

Related Views on News

TORRENT PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 2.0% (Quarterly Result Update)

Jan 28, 2020 | Updated on Jan 28, 2020

For the quarter ended December 2019, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 2.0% YoY). Sales on the other hand came in at Rs 20 bn (down 4.1% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

LUPIN Announces Quarterly Results (2QFY20); Net Profit Down 146.4% (Quarterly Result Update)

Nov 7, 2019 | Updated on Nov 7, 2019

For the quarter ended September 2019, LUPIN has posted a net profit of Rs 1 bn (down 146.4% YoY). Sales on the other hand came in at Rs 44 bn (up 10.3% YoY). Read on for a complete analysis of LUPIN's quarterly results.

TORRENT PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 36.3% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 36.3% YoY). Sales on the other hand came in at Rs 20 bn (up 5.9% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

LUPIN Announces Quarterly Results (1QFY20); Net Profit Up 49.3% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, LUPIN has posted a net profit of Rs 3 bn (up 49.3% YoY). Sales on the other hand came in at Rs 44 bn (up 14.6% YoY). Read on for a complete analysis of LUPIN's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 32.5% (Quarterly Result Update)

Jul 25, 2019 | Updated on Jul 25, 2019

For the quarter ended June 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 32.5% YoY). Sales on the other hand came in at Rs 20 bn (up 8.0% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

More Views on News

Most Popular

Multibaggers of the Next Decade(The 5 Minute Wrapup)

Feb 26, 2020

The one key ingredient to be seen amongst top multibaggers of the next decade.

The Next Few Days Are Crucial for Smallcap Investors - And 3 Must-Buy Stocks(Profit Hunter)

Feb 19, 2020

While I have been writing about the rebound in smallcaps for quite some time now... I have shied from the question - When exactly is the smallcap rebound happening. Well, the answer is now.

The Top 8 Trading Mistakes You Should Avoid(Fast Profits Daily)

Feb 18, 2020

Avoid these mistakes and your trading will turn much more profitable.

Corona Virus Could Trigger a Rally in this Stock(Profit Hunter)

Feb 20, 2020

A company which benefits from crude oil and coronavirus - if you would like to know more about it read this.

Why I Expect the Coronavirus to Benefit My Latest Trade Recommendation(Fast Profits Daily)

Feb 19, 2020

This is how my latest trade recommendation will benefit from the Coronavirus scare.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get our special report, Secret to Increasing Your Trading Profits Today Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Feb 28, 2020 (Close)

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA 5-YR ANALYSIS

COMPARE TORRENT PHARMA WITH

MARKET STATS